Ciphergen Posts Strong Revenue Growth, R&D Spending in Q3 | GenomeWeb

NEW YORK, Nov. 1 - Ciphergen Biosystems yesterday reported nearly two-fold growth in revenues and R&D spending during the third quarter amid a slightly widened net loss.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.